A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) — PANS  

Pediatric Acute-Onset Neuropsychiatric Syndrome Clinical Trial

Official title: A Multi-site, Open-Label, Pilot Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)

Status Active, not recruiting

Clinical Trial Summary

This study will evaluate the use of intravenous immunoglobulins (IVIG) at a dose of 1g/Kg/body weight given every three weeks for 6 infusions in pediatric subjects ages 4 - 16 years with moderate to severe PANS. The study will compare biomarkers and behavioral scales before treatment, after the last infusion, 2 months, and at a minimum 6 months post-treatment.

Clinical Trial Description

IVIG at an immunomodulatory dose of 1 g/Kg body weight has been known to induce suppression of systemic inflammation and has been used in the treatment of autoimmune diseases. It has been proven beneficial in inflammatory conditions affecting the nervous system. ;

Related Conditions & MeSH terms

• Pediatric Acute-Onset Neuropsychiatric Syndrome
• Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections
• Streptococcal Infections
• Syndrome

• NCT number: NCT03348618
• Study type: Interventional
• Source: IMMUNOe Research Centers
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: November 24, 2017
• Completion date: March 2020